CD10 y mesotelioma maligno. A propósito de un caso / CD10 and malignant mesothelioma. Report of a case

Aportamos un caso de mesotelioma maligno en unamujer de 37 años con antecedentes de laparoscopia por leiomiomasuterinos. El diagnostico de mesotelioma se estableciópor autopsia. El estudio inmunohistoquímico del tumormesotelial, reveló intensa positividad para CD10, y ausenciade inmunoreactividad para receptores de estrógenos y deprogesterona y calretinina. En nuestra serie de mesoteliomasobservamos que alrededor del 30% de ellos expresabanCD10. En la revisión de la Literatura se observó que aproximadamenteel 40% de los mesoteliomas, mostraban inmunoreactividadpara CD10. En conslusión nuestras observacionesmuestran que CD10 puede expresarse de formaextensa en los mesoteliomas, dato que puede ayudar al establecerun diagnóstico diferencial en estos casos

We report a case of malignant mesothelioma in a 37year-old woman treated for uterine leiomyomas. The diagnosisof mesothelioma was stablished based on autopsystudy. The immunohistochemical study of mesothelialtumor showed strong CD10 immunoreactivity. Our series ofmesotheliomas was also retrospectively studied with anti-CD10 and around 30% of them expressed CD10. Around40% of mestohelioma cases reported in the Literatureexpress CD10. We conclude that CD10 could be expressedin some mesothelial tumors, and may help to stablish a differentialdiagnosis in some cases

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.

Minimal inhibitory concentrations (MIC) and minimal fungicidal activity of albaconazole, voriconazole and fluconazole against 55 strains of Cryptococcus gattii, clinically or environmentally isolated in Spain and some Latin American countries, were assessed. By means of the microbroth method (National Committee for Clinical Laboratory Standards; document M27-A2), the geometric mean value for fluconazole was 5.01 microg/ml; however, MIC for 12.7% of isolates ranged from 16 to 32 microg/ml, suggesting increased resistance against fluconazole. Geometric mean values of 0.02 and 0.03 microg/ml for albaconazole and voriconazole, respectively, were found, indicating not only a higher susceptibility to these new azoles but also a better performance of albaconazole (P = 0.003). Minimal fungicidal concentrations were also very low for albaconazole and voriconazole (P<0.001; geometric mean values of 0.023 microg/ml and 0.07 microg/ml, respectively). Both azoles may be good alternatives for the treatment of C. gattii cryptococcosis.

DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.

Cryptococcus neoformans var. grubii (serotype A) was isolated from 12 soil samples mixed with pigeon droppings (16.9%) from 71 soil samples in Barcelona and rural areas of Catalonia. C. neoformans was not isolated from indoor dust and Eucalyptus debris. PCR fingerprinting was performed in 22 representative isolates and all of them corresponded to the VNI pattern. Susceptibility testing for the 22 isolates of C. neoformans var. grubii showed that all of them were susceptible to amphotericin B. Three isolates presented MICs (Minimal Inhibitory Concentrations) > or = 1 microg/ml to Itraconazole, five MICs > or = 1 microg/ml to ketoconazole and four were fluconazole resistant, (MICs > or = 64 microg/ml), while three of them were shown to have MICs > or = 1 microg/ml to voriconazole. In spite that all isolates presented the same DNA fingerprinting pattern, the susceptibility to antifungals is very variable. The possibility of acquiring cryptococcosis infection with primarily resistant environment strains is feasible.